TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively…
Pharmaceuticals, Biotechnology and Life Sciences
BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively…
Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or…
Raised $20.4 million in PIPE gross proceeds to support continued development of Company’s PMN310 and novel antibody therapeutics targeting toxic…
– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of…
-Summarizes third quarter 2023 financials of pre-Merger VBLT as of September 30th- -Third quarter financial information of Notable Labs, Inc.…
Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net…
Comparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants Comparison of the 24-month DDAF lesion growth…
MULTI-MILLION POUND BOOST FOR RESEARCH PROJECTS AIMED AT DEVELOPING NEW TESTS, TREATMENTS AND DEVICES FOR NEURODEGENERATIVE DISEASES Seven major research…
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of…
Third Quarter 2023 Revenue Grew 11% Year-Over-Year to $13.1 millionAdjusted EBITDA Growth of 95% Year-Over-YearEPS Growth of 77% Year-Over-Year TAMPA,…